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Abstract 
Aims 
To establish: (1a) CR availability and density, as well as (1b2) the nature of programs, 
and (23) compare these (a) by European region (geoscheme) and (b) to other high-
income countries (HICs). 
Methods  
A survey was administered to CR programs globally. Cardiac associations were 
engaged to facilitate program identification. Density was computed using Global 
Burden of Disease study ischemic heart disease (IHD) incidence estimates. Four HICs 
were selected for comparison (N=790 programs) to European data, and multi-level 
analyses performed. 
Results 
CR was available in 4039/444 (9088.96%) European countries. Data were collected in 
37 (94.8% country response rate). 455/1538 (29.6% response rate) program respondents 
initiated the survey. 
Program volumes (median=300) were greatest in Western European countries, 
but overall were higher than other HICs (p<.001). Across all the European HICs, there 
was on average only 1 CR spot per 7 IHD patients, with an unmet regional need of 
3,449,460  1,882,956 spots annually. 
Most programs were funded by social security (n=25, 59.5%; with significant 
regional variation, p<0.001), but in 72 (16.0%) patients paid some or all of program 
costs (or ~ 18.5% of the ~€150.0/program) out-of-pocket. Guideline-indicated 
conditions were accepted in ≥70% of programs (lower for stable coronary disease), with 
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no regional variation. Programs had a multidisciplinary team of 6.56±3.0 staff (number 
and type varied regionally; and European programs had more staff than other HICs), 
offering 8.5±1.5/10 core components (consistent with other HICs) over 24.8±26.0 hours 
(regional differences, p<0.05). 
Conclusion 
European CR capacity must be augmented. Where available, services were 
consistent with guidelines, but varied regionally. 
Keywords: Cardiac Rehabilitation; Europe; Survey 
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Introduction 
Similar to other high-income countries (HICs), cardiovascular diseases (CVD) are 
among the leading burdens of disease and disability in Europe1,2. Accordingly, it is the 
most expensive health condition to treat in terms of direct and indirect costs2; overall 
CVD is estimated to cost the EU economy €210 billion a year 2. CVD is a chronic 
condition, and hence secondary prevention is key to managing this massive burden on 
the healthcare system, as well as on patients and their families.  
Cardiac rehabilitation (CR) is an established model of care for secondary 
prevention, which is cost-effective, affordable, and averts costly downstream healthcare 
utilization3. Based on substantive evidence that participation is associated also with 
20% reductions in cardiovascular mortality and morbidity4,5, clinical practice 
guidelines6 for CVD revascularization and heart failure patients, among others, 
recommend referral to CR. Many European countries have CR guidelines7–16, as does 
the European Association of Preventive Cardiology6, a branch of the European Society 
of Cardiology, which specify the core components (e.g., initial assessment, structured 
exercise training, and risk factor management, including stress) which are to be 
delivered by a multi-disciplinary team of healthcare professionals with expertise in all 
the secondary prevention recommendations17. It is recommended programs offer a 
minimum dose of 12 sessions, although greater benefits could be achieved with more18, 
and these sessions can be delivered in an unsupervised setting if patients have barriers 
to participation19.  
The availability and nature of CR in European countries has been described 
following 2 previous surveys of national coordinators20,21. There have also been surveys 
of individual programs in Denmark22, Italy23, Portugal24–26, Spain27 and the United 
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Kingdom28–33, but this is only 5 of the approximately 44 countries in Europe. These 
surveys did characterize funding sources, volumes, CR dose, healthcare providers on 
CR teams, accepted indications, core components delivered, and delivery of alternative 
models (for a summary see Pesah et al.34). However, little is known about the capacity 
and density of CR. Moreover, assessment of individual programs across European 
countries with the same assessment tool has never been undertaken to enable 
comparison against the above guideline recommendations across the region, nor has 
there been any assessment and comparison of services with any other region in the 
world34. 
Accordingly, the objectives of this investigation were to: (1) characterize the 
availability, volumes, capacity and density of CR (a) by European country, (c) region, 
and (c) in relation to other HICs; (2) characterize the following aspects of CR: (a) who 
pays for services and costs, (b) type of patients served, (c) number and types of 
healthcare professionals on the CR team, (d) number of program sessions / dose, (e) 
core components delivered, and (f) delivery of alternative models, again by European 
country, region, and in comparison to other HICs. 
Methodology 
Design & Procedure 
This research was cross-sectional in design; detailed methods are reported 
elsewhere (Supervia et al., under review). In brief, countries where CR services were 
available were identified first through previous reviews35,36. In countries where CR 
services were not suspected to be available, the internet was searched and major CR and 
cardiology societies were contacted to identify any programs or verify lack thereof.   
For each country identified to offer CR, first available CR or cardiac society 
leadership were contacted (e.g., European Association of Preventive Cardiology). If 
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there was no society available or response, “champions” were identified, and in the case 
of European countries, the European Society of Cardiology national CVD coordinators 
were contacted. Identified leaders were sent an e-mail requesting their collaboration to: 
(a) determine the number of programs in their country, and (b) assist with 
administration of the survey to each program in their country.  
Each identified program was emailed with the request to complete the survey. 
Informed consent was secured through an online form. The survey was administered 
through REDCap, with data collection occurring from June 2016 to December 2017.  
Sample  
For the global study, the sample consisted of all CR programs identified in the world 
that offer services to patients following an acute cardiac event or hospitalization (i.e., 
Phase II). The inclusion criteria were CR programs that offered: (1) initial assessment, 
(2) structured exercise, and (3) at least one other strategy to control CV risk factors. 
For the purposes of this study, CR programs in European countries (according to 
the geoscheme regions37; small islands and jurisdictions were excluded, e.g., Aland 
islands, Vatican City) as well as in 4 other HICs (United States, Canada, Australia and 
New Zealand; i.e., countries most comparable to European HICs) were selected.  
Measures 
With regard to the first objective, CR availability referred to existence of ≥1 
program in a country. Program volume was defined as the median number of patients 
served by a program annually (program-reported in survey, described below). National 
and regional CR capacity were computed by multiplying the median number of patients 
a program could serve annually (program-reported in survey) among the responding 
programs in a given country or region respectively, multiplied by the total number of 
programs in that jurisdiction (ascertained from literature and/or champion). Please note 
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for countries where no surveys were completed, capacity was computed by multiplying 
the number of programs by median regional program volumes. Lastly, to compute 
density, ischemic heart disease (IHD) incidence was pulled from the Global Burden of 
Disease study38. Then, the ratio of capacity (as computed above) per annual incident 
IHD case was computed. Unmet need was computed as IHD incidence minus national 
capacity. 
Development of the survey is described in detail elsewhere39. In short, items 
were based on previous national/regional CR programs surveys20,40. Most items had 
forced-choice response options, and skip-logic was used to obtain more detail where 
applicable. The survey is available elsewhere (Supervia et al., under review). 
The following variables were assessed: (i) who funds the program (i.e., private 
sources such as healthcare insurance, public sources such as government, or a 
combination of these sources [i.e., hybrid]), (ii) the type (e.g., myocardial infarction, as 
well as non-cardiac indications) and number of patients served per session (as well as 
staff-to-patient ratio), (iii) the number and types of healthcare professionals on the CR 
team (part-time staff were counted as 0.5), (iv) dose of CR (in hours; i.e., sessions per 
week x duration in weeks x duration of exercise sessions in minutes/60); (v) the type 
and number of core components delivered (of 10; i.e., initial assessment [including risk 
factors assessed and type of functional capacity test], risk stratification, structured 
exercise, patient education, risk factor management, nutrition counselling, stress 
management, smoking cessation interventions, prescription or titration of medication, 
and communication with a primary healthcare provider), and (vi) whether the program 
offers alternative CR models (i.e., home or community-based programs, or hybrid 
models where patients transition from supervised to unsupervised settings). 
Data analysis 
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SPSS version 24 was used for analysis41. All initiated surveys were included. 
The number of responses for each question varied due to missing data (e.g., respondent 
did not answer a question due to lack of willingness or potential inapplicability, use of 
skip logic); for descriptive analyses, percentages were computed with the denominator 
being the number of responses for a specific item. Descriptive statistics were used to 
characterize availability, volume, capacity, density, as well other closed-ended items in 
the survey (e.g., funding sources, healthcare professionals on the CR team, and core 
components delivered). 
All open-ended responses were coded / categorized. Aspects of CR were then 
compared by nationally, regionally and versus other HICs using generalized linear 
mixed models to take into consideration the hierarchical nature of data (e.g., CR 
programs nested within countries) where applicable and there were sufficient data in 
each country for estimates to be generated. Otherwise ANOVA or chi-square tests were 
applied. 
Results 
As shown in Table 1, CR is available in 4039 (9088.96%) of the 44 European countries. 
Data were collected in 37 (92.5%) countries. Of these, 8 (Belarus, Bosnia and 
Herzegovina, Bulgaria Romania, Russia, Moldova, Republic of Northern Macedonia 
and Serbia) were not considered high-income as per the World Bank42. No response was 
obtained from: Montenegro, Norway and Luxembourg (Figure 1). 
In terms of programs, 455/1538 responded in Europe (29.6%; Table 1). Please 
note a subsample of programs only was surveyed in Austria and Scotland (1-2 programs 
per health board/region for the latter) due to champion preference. Of the 4 HICs 
selected for comparison that had CR, 234 surveys were initiated (30.1% response rate). 
Volumes, Capacity and Density 
Formatted: Highlight
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The number of programs per country and region is shown in Table 1. Of 
responding programs, 287 (65.9%) reported being situated in an urban area, and 83 
(19.1%) in a suburban area. Overall, 337 (78.9%) were in a hospital (academic, 
community or rehabilitation); of which 155 (45.9%) were academic or tertiary centres. 
Two hundred and four (51.1%) programs reported that there was another CR program 
within a 20km radius (vs. 87 [38.7%] in other HICs). 
Volumes, capacity and density are shown in Supplemental Table 1. Volumes per 
program (median=300) were greatest in Western Europe (median=515). Program 
volumes were significantly higher than in other HICs (p<0.001). Median national 
capacity was 4170 CR spots/country (7563 for Northern, 3000 for Eastern, 2300 for 
Southern and 27450 for Western). It was significantly higher than the other HICs.  
Overall European density was 1 spot per a median of 7 IHD patients / year / 
country (per 2 for Northern countries, 21 for Eastern, 13 for Southern and per 4 patients 
for Western region; Supplemental Table 1). In other HICs, the density was on average 1 
spot for 2 patients. As shown in Table 1, unmet CR need was substantially higher in 
Eastern Europe, particularly due to the dearth of CR in Russia. 
Nature of CR Services 
Program responders were asked to report who pays for their services, and could check 
all applicable sources (n=112, 25.7% reported >1 source; Table 2). Overall, 312 
(69.5%) programs reported government funding (p=0.11 for regional variation), 115 
(25.6%) reported hospital / clinical centre funding (with significant regional variation, 
p=0.001), 77 (17.1%) reported private health insurance (p<0.01), and 72 (16.0%) 
reported the patient pays (p=0.15). Funding source in Europe was not different than 
other HICs (p=0.50).   
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In 15 (3.3%) programs, the sole source of funding was the patient (p<0.001; data 
shown by country elsewhere43). Table 2 also displays the proportion of the total 
program cost patients pay when they are a source of CR financing, and the associated 
estimated cost to them (purchasing power parity values by country shown elsewhere43). 
Direct cost to patient differed between regions where they paid (p<0.05), with the 
Southern region having the highest cost (€809.21). The estimated cost to deliver a full 
course of CR (as per dose shown in Figure 2) is also shown; cost differed between 
regions (p<0.001), with the Western and Southern region having the highest cost 
(€2,163 and €3,090). There was also no difference from other HICs for cost to deliver a 
full course of CR (p>.05).  
The most common type of patients accepted in CR programs are shown in Table 
3 (shown by country in Supervia, M. et al., under review). There was significant 
regional variation for heart failure (accepted less often in Southern Europe), and the 
only significant difference between European HICs and other HICs was for valve 
procedures (accepted more often in European HICs). Other accepted indications 
included: heart transplant (n=282, 63.8%), congenital heart disease (n=266, 60.2%), 
patients with mechanical circulatory support devices (n=188, 42.5%) and implanted 
devices for rhythm control (n=187, 42.3%).  Many programs also accepted patients with 
non-cardiac indications, namely: intermittent claudication / peripheral vascular disease 
(n=149, 33.7%), diabetes (n=122, 27.6%), lung disease (n=103, 23.3%), stroke (n=74, 
16.7%) and cancer (n=50, 11.3%). 
The number and nature of healthcare professionals on CR teams is shown in 
Table 4 (shown by country in Supervia, M. et al., under review); programs on average 
had 6.5 staff members, most commonly a nurse, physiotherapist, cardiologist, dietitian 
and administrative assistant. There was significant regional variation in total number 
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(higher in west than north), and type (i.e., fewer cardiologists [among other physicians], 
psychologists and administrative assistants in north) of providers. When compared to 
other HICs, Europe had significantly more staff overall, with more physiotherapists, 
cardiologists, physiatrists, and sports medicine physicians as well as psychologists and 
psychiatrists on their CR teams.  
During exercise sessions, there was most commonly a physiotherapist (n=248, 
82.7%) and a nurse (n=184, 63.2%) present. The median number of patients per 
supervised exercise session was 9 (Q25-Q75=6-12). The overall dose of CR was 
24.8±26.0 hours (median=16.0; Figure 2; median frequency was 2.5 sessions per week, 
and program duration was 8.0 weeks). There was significant variation by region 
(p<0.05), with higher doses in the Southern and Western regions. Dose was not 
significantly different in Europe than other HICs.  
Programs offered 8.5/11 “core” components on average (Table 5; shown by 
country in Supervia, M. et al., under review), this did not vary significantly by region. 
There was some significant regional variation in provision of return-to-work 
counselling (higher in west), among some other elements. There were some significant 
differences in delivery of components in European versus other HICs (but the same 
number offered overall), namely counselling for return-to-work, prescription and /or 
titration of medications and functional capacity testing (by multiple means) were more 
frequently delivered in European HICs. Risk factors assessed pre-program, and 
equipment to deliver components are reported elsewhere by country (Supervia, M. et al., 
under review). 
 Finally, alternative CR model delivery is shown in Figure 1; 119 (33.5%) 
programs reported delivery of any alternative model (more detail on type is shown in 
Ghisi, G. et al.44). Twenty-five (21.0% of programs that offered alternative models, or 
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5.5% of all programs) programs reported using smartphones, an “app”, or text 
messaging with patients (i.e., some form of eCR). There was significant variation by 
region (p<.05), but there was not significantly different alternative model 
implementation when compared to other HICs (p>.05). 
Discussion 
For the first time, the unmet need for CR has been estimated in Europe, with 
well over 3 million more spots needed per year to treat IHD patients alone, and the 
grossest unmet need in Eastern Europe. Where available, countries have a median of 16 
programs each treating 300 patients (with guideline-indicated conditions accepted in 
≥85% of programs, but stable coronary disease less so) per year. Government is the 
most common CR funding source for programs that cost a mean of ~€1850, but in 
approximately 40% of programs patients are paying out-of-pocket (for 35% of the 
program cost or ~€500/patient/program). Patients are prescribed a median of 167 hours 
of CR (which is considered sufficient to achieve the benefits)18, covering a median of 
8.5 core components (with significant variation in delivery of return-to-work 
counselling needing to be addressed, and more consistent delivery of tobacco cessation 
interventions needed as well) delivered by 6.5 staff (with the type differing by region 
and varying from the composition in other HICs).  
No study has ever attempted to quantify density and unmet need in Europe, so 
this is a first and best attempt. The overall value for unmet need does not take into 
consideration patients who may have contraindications to participation (not to exercise 
as patients should receive the other core components), or heart failure patients who are 
also indicated, so more research is needed. While we did not compute unmet need in all 
global regions, when comparing density of CR in other regions (only considering 
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countries with CR) of the globe, Europe and the Western Pacific have the best and quite 
comparable density, with Africa the worst. 
Moreover, this is the first ever survey of all CR programs in Europe (although 
the European Society of Preventive Cardiology has recently re-surveyed national 
coordinators [but not individual programs]45, and so we look forward to those results 
becoming available). Results are fairly consistent with the previous surveys of programs 
in Europe34, with regard to funding source, accepted indications, most common 
healthcare providers, dose, as well as the low availability of CR in alternative settings.  
         The implications of this work are many. Policy recommendations include 
advocacy for better reimbursement of CR services by public sources and private 
healthcare insurance so patients are not paying out-of-pocket46. Recommendations to 
augment capacity include initiating services in countries without CR, and expanding 
provision of eCR47,48, particularly in Russia, Belarus and Greece where unmet need is 
greatest. Program-level innovations recommended on the basis of this work include 
more consistent provision of return-to-work counselling to optimize life functioning for 
patients and reduce the negative impacts of CVD on the economy. Moreover, given 
tobacco cessation is the most impactful change for secondary prevention49, clearly 
universal delivery should be pursued. Indeed, results from EUROASPIRE IV 
demonstrate that CR participants are not quitting tobacco at a rate greater than non-
participants50,  bolstering our call for more focus on this component in European CR 
programs.  
              In terms of directions for future research, there are several important avenues to 
be pursued. First, while the survey assessed structure and process indicators of CR 
programs, how these translate to patient outcomes cannot be ascertained. Field tests of 
CR programs, examining the “how” and what is delivered in each core component, and 
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in non-supervised settings is warranted, as well as actual dose received by patients (i.e., 
adherence to prescribed sessions). Europe did have a multinational registry51, and it 
would be ideal to link this structural program data to the patient-level data in a registry 
to determine the degree of quality of CR in Europe. Given there are other countries that 
also have registries52, again CR delivery in Europe could be benchmarked against these 
other countries.  
This study has several limitations. First, there may be ascertainment bias or 
under-estimation of capacity due to failure to identify programs or differences in the 
nature of programs identified to those that may have not been identified. Second, 
response rates to online surveys are notoriously low. The country response rate was 
high, but the program rate was 30% in the current study, which is fair, but suggests 
there may be bias (potentially higher-quality programs are better-represented). Third, 
respondents may have been inclined to respond in a socially-desirable manner, such that 
results were skewed to reflect better provision of CR. However, participants were 
informed that their responses were confidential. The recent data from EUROASPIRE 
IV does suggest that provision of some CR components is insufficient to achieve target 
risk reductions50. Fourth, CR in Europe was compared to only four other HICs; 
comparisons to other HICs in future could provide useful information. Finally, multiple 
comparisons were performed, and there were few respondents in some countries, and 
hence caution is necessary when interpreting the findings. 
Conclusion 
 There are >150038 CR programs across Europe, existing in ~90% of countries. 
However, there is only one spot for every 7 patients in need (with particularly great 
need for capacity increases in Eastern Europe), although this density is quite good 
compared to other regions of the globe. Program delivery is highly consistent with 
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European CR guidelines, although there is significant regional variation in relation to 
funding sources, costs to patients, the nature of providers on CR teams, dose and 
alternative model delivery. Moreover, the nature of services is quite consistent with that 
in other comparable HICs, except in terms of program volumes, the number and nature 
of providers on CR teams and the type of core components offered.  
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